Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia

Patients receiving targeted cancer treatments such as tyrosine kinase inhibitors (TKIs) have been classified in the clinically extremely vulnerable group to develop severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), including patients with chronic myeloid leukaemia (CML) taking TKIs. In a...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrington, Patrick, Doores, Katie J., Radia, Deepti, O’Reilly, Amy, Lam, Ho Pui Jeff, Seow, Jeffrey, Graham, Carl, Lechmere, Thomas, McLornan, Donal, Dillon, Richard, Shanmugharaj, Yogita, Espehana, Andreas, Woodley, Claire, Saunders, Jamie, Curto-Garcia, Natalia, O'Sullivan, Jennifer, Raj, Kavita, Kordasti, Shahram, Malim, Michael H., Harrison, Claire, de Lavallade, Hugues
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Covid‐19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239833/
https://www.ncbi.nlm.nih.gov/pubmed/34085278
http://dx.doi.org/10.1111/bjh.17568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239833/
https://www.ncbi.nlm.nih.gov/pubmed/34085278
http://dx.doi.org/10.1111/bjh.17568

Ejemplares similares